251 related articles for article (PubMed ID: 26205085)
1. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
Fink EE; Mannava S; Bagati A; Bianchi-Smiraglia A; Nair JR; Moparthy K; Lipchick BC; Drokov M; Utley A; Ross J; Mendeleeva LP; Savchenko VG; Lee KP; Nikiforov MA
Leukemia; 2016 Jan; 30(1):104-11. PubMed ID: 26205085
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
Ri M
Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614
[TBL] [Abstract][Full Text] [Related]
3. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
4. The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.
Yin Y; Qi X; Qiao Y; Liu H; Yan Z; Li H; Liu Z
Curr Cancer Drug Targets; 2019; 19(1):50-64. PubMed ID: 30289077
[TBL] [Abstract][Full Text] [Related]
5. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
6. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
8. Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca
Lee AR; Seo MJ; Kim J; Lee DM; Kim IY; Yoon MJ; Hoon H; Choi KS
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817163
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
11. Txnrd2 Attenuates Early Brain Injury by Inhibition of Oxidative Stress and Endoplasmic Reticulum Stress via Trx2/Prx3 Pathway after Intracerebral Hemorrhage in Rats.
Liu X; Hong E; Xie J; Li J; Ding B; Chen Y; Xia Z; Jiang W; Lv H; Yang B; Chen Y
Neuroscience; 2024 May; 545():158-170. PubMed ID: 38513765
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial thioredoxin reductase is essential for early postischemic myocardial protection.
Horstkotte J; Perisic T; Schneider M; Lange P; Schroeder M; Kiermayer C; Hinkel R; Ziegler T; Mandal PK; David R; Schulz S; Schmitt S; Widder J; Sinowatz F; Becker BF; Bauersachs J; Naebauer M; Franz WM; Jeremias I; Brielmeier M; Zischka H; Conrad M; Kupatt C
Circulation; 2011 Dec; 124(25):2892-902. PubMed ID: 22144571
[TBL] [Abstract][Full Text] [Related]
13. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
14. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N; Hideshima T; Shimomura T; Suzuki R; Ohguchi H; Rizq O; Kikuchi S; Yoshida Y; Cottini F; Jakubikova J; Cirstea D; Gorgun G; Minami J; Tai YT; Richardson PG; Utsugi T; Iwama A; Anderson KC
Cancer Res; 2014 Aug; 74(16):4458-69. PubMed ID: 24934808
[TBL] [Abstract][Full Text] [Related]
15. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
16. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
18. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K
Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression.
Moriya S; Kazama H; Hino H; Takano N; Hiramoto M; Aizawa S; Miyazawa K
PLoS One; 2023; 18(12):e0295273. PubMed ID: 38039297
[TBL] [Abstract][Full Text] [Related]
20. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]